OptimizeRx Corporation (OPRX) 株式分析

企業概要

OptimizeRx Corporation is a digital healthcare technology enterprise that specializes in leveraging machine learning methodologies to generate dynamic audiences through predictive analytics, alongside privacy-first micro-neighborhood targeting solutions. The company operates within the broader healthcare sector, specifically functioning in the Health Information Services industry, where it provides essential data infrastructure for pharmaceutical and life sciences clients. Its current market capitalization stands at $121.95M, supported by an annual revenue stream of $109.43M and an operational workforce of 132 employees. These valuation and revenue figures suggest that the company maintains a mid-cap profile, indicating a position that has moved beyond initial seed-stage ventures but remains relatively small compared to large-cap pharmaceutical giants, thereby reflecting a niche focus on specialized digital activation platforms rather than broad consumer market dominance.

財務健全性

The company reported a total revenue of $109.43M over the trailing twelve months, yielding a net income of $5.13M and an EBITDA of $16.39M, which highlights a significant gap between operating earnings and net profit attributable to substantial non-operating expenses or tax obligations. This disparity reveals a cost structure where nearly 53% of the EBITDA is consumed by interest, taxes, depreciation, or amortization, leaving a final profit margin that is considerably thinner than the operating performance suggests. The firm generated free cash flow of $16.27M, a figure that underscores its strong financial flexibility and ability to fund operations without relying on external equity financing or incurring excessive new debt. Operating leverage is evident in the margins, with a gross margin of 67.3% indicating high scalability in delivering digital services, while an operating margin of 27.7% demonstrates efficient internal management of costs before interest and taxes. However, the final profit margin sits at 4.7%, signaling that the bottom line is highly sensitive to interest expenses or one-time charges. On the balance sheet, the company holds $23.36M in cash against $26.10M in debt, resulting in a debt-to-equity ratio of 20.35, which classifies the capital structure as moderately leveraged given the relatively small equity base implied by the ratio. Liquidity is robust, evidenced by a current ratio of 3.04, which indicates that the company possesses more than three times the current assets necessary to cover its short-term liabilities. Return metrics show a return on equity of 4.2% and a return on assets of 4.3%, figures that reveal a modest effectiveness in generating returns relative to the capital invested, consistent with a capital-intensive or low-margin service model.

バリュエーション評価

The trailing twelve-month P/E ratio is 24.07, whereas the forward P/E is projected at 5.72, a stark divergence that implies the market expects a dramatic increase in future earnings or a significant re-rating of the stock price to align with current valuations. The price-to-book ratio stands at 0.95, suggesting that the company is currently trading at a discount to its net asset value, which may indicate a lack of market premium or concerns regarding the quality of its intangible assets. Alternative valuation metrics such as the price-to-sales ratio of 1.11 and an EV/EBITDA of 7.61 provide further context, showing that the company trades at a premium relative to sales but at a reasonable multiple of earnings before interest, taxes, depreciation, and amortization. In terms of trading range, the stock has fluctuated between a 52-week high of $22.25 and a 52-week low of $5.54, meaning the current price sits significantly below the yearly peak, reflecting a period of substantial volatility or correction. The beta value of 1.28 indicates that the stock's price volatility is approximately 28% higher than that of the broader market, exposing investors to greater systemic risk during market downturns.

Growth & Income

Revenue growth over the past year recorded a decline of -0.2%, while earnings growth is marked as N/A, indicating that the company is currently in a stabilization phase or experiencing headwinds that prevent positive year-over-year expansion. Since the earnings growth figure is not available, it is impossible to determine if earnings are growing faster or slower than revenue, but the negative revenue trend suggests a contraction in the core business or a loss of market share in the digital healthcare technology space. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests all available earnings into growth initiatives, debt reduction, or share buybacks rather than returning capital to shareholders via cash distributions. Consequently, the overall growth and income profile is characterized by a reliance on capital appreciation and operational turnaround rather than income generation through dividends, presenting a high-risk, high-reward scenario dependent on future revenue recovery.